Access to this article is restricted until 6 months after publication by request of the publisher.. Restriction lift date: 2024-01-12
The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside
Mitsikostas, Dimos D.
Maassen van den Brink, Antoinette
Springer Nature Ltd.
Migraine is a leading cause of disability in more than one billion people worldwide, yet it remains universally underappreciated, even by individuals with the condition. Among other shortcomings, current treatments (often repurposed agents) have limited efficacy and potential adverse effects, leading to low treatment adherence. After the introduction of agents that target the calcitonin gene-related peptide pathway, another new drug class, the ditans — a group of selective serotonin 5-HT1F receptor agonists — has just reached the international market. Here, we review preclinical studies from the late 1990s and more recent clinical research that contributed to the development of the ditans and led to their approval for acute migraine treatment by the US Food and Drug Administration and the European Medicines Agency.
Migraine , Ditans , Selective serotonin 5-HT1F receptor agonists
Mitsikostas, D. D., Waeber, C., Sanchez-del-Rio, Raffaelli, B., Ashina, H., van den Brink, A. M., Andreou, A., Pozo-Rosich, P., Rapoport, A., Ashina, M. and Moskowitz, M. A. (2023) 'The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside', Nature Reviews Neurology, 19, pp. 489–505. doi: 10.1038/s41582-023-00842-x
© 2023, Springer Nature Limited. This is a post-peer-review, pre-copyedit version of an article published in Nature Reviews Neurology. The final authenticated version is available online at: https://doi.org/10.1038/s41582-023-00842-x